Allakos Inc. – NASDAQ:ALLK
Allakos stock price today
$0.329
-0.97
-74.68%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Allakos stock price monthly change
+51.11%
month
Allakos stock price quarterly change
+51.11%
quarter
Allakos stock price yearly change
-52.55%
year
Allakos key metrics
Market Cap | 113.46M |
Enterprise value | 235.27M |
P/E | -0.84 |
EV/Sales | N/A |
EV/EBITDA | -0.76 |
Price/Sales | N/A |
Price/Book | 0.88 |
PEG ratio | 0.84 |
EPS | -2.45 |
Revenue | N/A |
EBITDA | -192.56M |
Income | -214.44M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAllakos stock price history
Allakos stock forecast
Allakos financial statements
| Jun 2023 | 0 | -35.12M | |
|---|---|---|---|
| Sep 2023 | 0 | -45.62M | |
| Dec 2023 | 10.75M | -62.55M | -581.55% |
| Mar 2024 | 0 | -71.14M |
| Mar 2024 | 0 | -71.14M | |
|---|---|---|---|
| Sep 2025 | 0 | -20.35M | |
| Oct 2025 | 0 | -20.54M | |
| Dec 2025 | 0 | -22.30M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 319196000 | 64.21M | 20.12% |
|---|---|---|---|
| Sep 2023 | 283495000 | 62.45M | 22.03% |
| Dec 2023 | 243610000 | 74.79M | 30.7% |
| Mar 2024 | 177312000 | 73.32M | 41.36% |
| Jun 2023 | -32.59M | 6.12M | 0 |
|---|---|---|---|
| Sep 2023 | -29.47M | 31.54M | 1.07M |
| Dec 2023 | -24.26M | 20.18M | 696K |
| Mar 2024 | -32.54M | 9.02M | 132K |
Allakos alternative data
| Aug 2023 | 123 |
|---|---|
| Sep 2023 | 123 |
| Oct 2023 | 123 |
| Nov 2023 | 123 |
| Dec 2023 | 123 |
| Jan 2024 | 123 |
| Feb 2024 | 123 |
| Mar 2024 | 131 |
| Apr 2024 | 131 |
| May 2024 | 131 |
| Jun 2024 | 131 |
| Jul 2024 | 131 |
Allakos other data
69.05%
+7.17%
of ALLK is owned by hedge funds
123
-7
37.16M
+3.71M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jun 2024 | 0 | 87064 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | RADFORD HARLAN BAIRD officer: Chief Financial Officer | Common Stock | 87,064 | $1.01 | $87,935 | ||
Purchase | WALKER PAUL EDWARD director | Common Stock | 3,386,400 | $5.02 | $16,999,728 | ||
Purchase | WALKER PAUL EDWARD director | Common Stock | 597,600 | $5.02 | $2,999,952 | ||
Purchase | JANNEY DANIEL director, 10 percent owner | Common Stock | 475,000 | $5.02 | $2,384,500 | ||
Option | JAMES STEVEN P director | Stock Option (Right to buy) | 4,000 | $0.53 | $2,100 | ||
Sale | JAMES STEVEN P director | Common Stock | 4,000 | $108.12 | $432,480 | ||
Option | JAMES STEVEN P director | Common Stock | 4,000 | $0.53 | $2,100 | ||
Option | TOMASI ADAM officer: Presiden.. | Common Stock | 64,148 | $4.31 | $276,670 | ||
Option | TOMASI ADAM officer: Presiden.. | Stock Option (Right to buy) | 64,148 | $4.31 | $276,670 | ||
Sale | TOMASI ADAM officer: Presiden.. | Common Stock | 20,000 | $0.69 | $13,760 |
| Patent |
|---|
Application Filling date: 31 Jul 2020 Issue date: 18 Aug 2022 |
Application Filling date: 5 Nov 2021 Issue date: 26 May 2022 |
Application METHODS AND COMPOSITIONS FOR TREATING MAST CELL GASTRITIS, MAST CELL ESOPHAGITIS, MAST CELL ENTERITIS, MAST CELL DUODENITIS, AND/OR MAST CELL GASTROENTERITIS Filling date: 14 Feb 2020 Issue date: 5 May 2022 |
Application Filling date: 3 May 2019 Issue date: 12 Aug 2021 |
Application Filling date: 31 Jul 2020 Issue date: 15 Apr 2021 |
Application Filling date: 11 Jan 2019 Issue date: 25 Feb 2021 |
Grant Filling date: 16 Jun 2016 Issue date: 15 Sep 2020 |
Application Filling date: 4 May 2018 Issue date: 27 Aug 2020 |
Application Filling date: 20 Feb 2020 Issue date: 11 Jun 2020 |
Application Filling date: 4 May 2018 Issue date: 14 May 2020 |
| Insider | Compensation |
|---|---|
| Dr. Robert Alexander Ph.D. (1970) Chief Executive Officer & Director | $1,450,000 |
| Dr. Adam L. Tomasi Ph.D. (1970) Pres & Chief Operating Officer | $1,090,000 |
| Dr. Henrik Sandvad Rasmussen (1959) Strategic Advisor | $880,070 |
| Mr. Mark Asbury (1963) Chief Legal Officer & Gen. Counsel | $719,870 |
-
What's the price of Allakos stock today?
One share of Allakos stock can currently be purchased for approximately $0.33.
-
When is Allakos's next earnings date?
Unfortunately, Allakos's (ALLK) next earnings date is currently unknown.
-
Does Allakos pay dividends?
No, Allakos does not pay dividends.
-
How much money does Allakos make?
Allakos has a market capitalization of 113.46M.
-
What is Allakos's stock symbol?
Allakos Inc. is traded on the NASDAQ under the ticker symbol "ALLK".
-
What is Allakos's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Allakos?
Shares of Allakos can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Allakos's key executives?
Allakos's management team includes the following people:
- Dr. Robert Alexander Ph.D. Chief Executive Officer & Director(age: 55, pay: $1,450,000)
- Dr. Adam L. Tomasi Ph.D. Pres & Chief Operating Officer(age: 55, pay: $1,090,000)
- Dr. Henrik Sandvad Rasmussen Strategic Advisor(age: 66, pay: $880,070)
- Mr. Mark Asbury Chief Legal Officer & Gen. Counsel(age: 62, pay: $719,870)
-
How many employees does Allakos have?
As Jul 2024, Allakos employs 131 workers.
-
When Allakos went public?
Allakos Inc. is publicly traded company for more then 7 years since IPO on 19 Jul 2018.
-
What is Allakos's official website?
The official website for Allakos is allakos.com.
-
Where are Allakos's headquarters?
Allakos is headquartered at 975 Island Drive, Redwood City, CA.
-
How can i contact Allakos?
Allakos's mailing address is 975 Island Drive, Redwood City, CA and company can be reached via phone at +65 05975002.
Allakos company profile:
Allakos Inc.
allakos.comExchange:
NASDAQ
Full time employees:
131
Industry:
Biotechnology
Sector:
Healthcare
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
975 Island Drive
Redwood City, CA 94065
Redwood City, CA 94065
CIK: 0001564824
ISIN: US01671P1003
CUSIP: 01671P100
